Article
Medicine, General & Internal
Katarina Lopusna, Pawel Nowialis, Jana Opavska, Ajay Abraham, Alberto Riva, Rene Opavsky
Summary: The study revealed that Dnmt3b's catalytic activity is largely dispensable for mouse development but critical for preventing tumorigenesis by controlling events involved in cellular transformation. The lack of Dnmt3b's catalytic activity promoted fibroblast transformation in vitro and accelerated the development of certain types of leukemia and lymphoma in vivo.
Article
Multidisciplinary Sciences
Takafumi Nakayama, Masaaki Sunaoshi, Yi J. Shang, Mizuki Takahashi, Takato Saito, Benjamin Blyth, Yoshiko Amasaki, Kazuhiro Daino, Yoshiya S. Shimada, Akira S. Tachibana, Shizuko S. Kakinuma
Summary: Calorie restriction (CR) can suppress the occurrence of both spontaneous and chemically- or radiation-induced carcinogenesis. However, it is not effective in preventing the development of thymic lymphoma (TL). In this study, the genomic alterations of TLs were investigated to understand the underlying resistance mechanism of CR.
Article
Immunology
Mark P. Roberto, Gabriele Varano, Rosa Vinas-Castells, Antony B. Holmes, Rahul Kumar, Laura Pasqualucci, Pedro Farinha, David W. Scott, David Dominguez-Sola
Summary: FOXO1 mutations in B-NHL lead to hyperactivation of PI3K and SAPK/JNK signaling in B cell lines, enhancing cell survival under stressful conditions and providing a competitive advantage. These mutations also disrupt GC homeostasis and predict poor clinical outcomes in human B-NHL cases.
Review
Medicine, Research & Experimental
Jianan Xu, Yuanyuan Sun, Weineng Fu, Shuang Fu
Summary: Myc target 1 (MYCT1), located at 6q25.2, is a crucial player in cancer development with widely distributed expression in cells and variable subcellular localization across different cancer types. It is regulated by multiple transcription factors and aberrant expression of MYCT1 impacts key biological processes and tumor immune responses in cancer cells. Despite some debated functions, MYCT1 holds undeniable significance in cancer development. This review aims to comprehensively examine the relationship between MYCT1 and cancer, providing valuable insights for cancer diagnosis and treatment.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Biology
Elisa Redl, Raheleh Sheibani-Tezerji, Crhistian de Jesus Cardona, Patricia Hamminger, Gerald Timelthaler, Melanie Rosalia Hassler, Masa Zrimsek, Sabine Lagger, Thomas Dillinger, Lorena Hofbauer, Kristina Draganic, Andreas Tiefenbacher, Michael Kothmayer, Charles H. Dietz, Bernard H. Ramsahoye, Lukas Kenner, Christoph Bock, Christian Seiser, Wilfried Ellmeier, Gabriele Schweikert, Gerda Egger
Summary: Malignant transformation relies on genetic and epigenetic events leading to dysregulated gene expression and chromatin changes. A lymphoma model reveals that transformation shifts thymic cell populations to an undifferentiated immunophenotype, accompanied by induction of the MYC-NOTCH1 axis and deregulation of key epigenetic enzymes. The faithful maintenance of tumor-specific methylation through DNMT1 is critical for sustained proliferation and tumorigenesis, even in the presence of oncogenic signaling from NPM-ALK.
LIFE SCIENCE ALLIANCE
(2021)
Article
Biochemistry & Molecular Biology
Hai Vu Nguyen, Cassandra J. Vandenberg, Mikara R. Robati, Ashley P. Ng, Suzanne Cory
Summary: The importance of c-MYC in regulating lymphopoiesis and promoting lymphomagenesis is well-established. Far less appreciated is the vital supporting role of MYC's relative MNT. Using genetic deletion experiments in mice, the researchers demonstrate that loss of MNT leads to enhanced apoptosis and reduces the development of T lymphomas in both normal and irradiated mice. These findings suggest that targeting MNT could be a promising strategy for treating T and B lymphoid malignancies.
CELL DEATH AND DIFFERENTIATION
(2023)
Article
Biochemistry & Molecular Biology
Chun Gong, Joanna A. Krupka, Jie Gao, Nicholas F. Grigoropoulos, George Giotopoulos, Ryan Asby, Michael Screen, Zelvera Usheva, Francesco Cucco, Sharon Barrans, Daniel Painter, Nurmahirah Binte Mohammed Zaini, Bjoern Haupl, Susanne Bornelov, Igor Ruiz De Los Mozos, Wei Meng, Peixun Zhou, Alex E. Blain, Sorcha Forde, Jamie Matthews, Michelle Guet Khim Tan, G. A. Amos Burke, Siu Kwan Sze, Philip Beer, Cathy Burton, Peter Campbell, Vikki Rand, Suzanne D. Turner, Jernej Ule, Eve Roman, Reuben Tooze, Thomas Oellerich, Brian J. Huntly, Martin Turner, Ming-Qing Du, Shamith A. Samarajiwa, Daniel J. Hodson
Summary: Loss-of-function mutations in DDX3X can buffer MYC-induced proteotoxic stress, and male B cell lymphomas have the capacity to compensate for this loss by ectopically expressing DDX3Y.
Article
Multidisciplinary Sciences
Jaqueline Loaeza-Loaeza, Angel Josue Cerecedo-Castillo, Hugo Alberto Rodriguez-Ruiz, Yaneth Castro-Coronel, Oscar Del Moral-Hernandez, Felix Recillas-Targa, Daniel Hernandez-Sotelo
Summary: DNA methylation is an important epigenetic modification that regulates gene expression in mammalian cells. Abnormal DNA methylation in gene promoters is common in human cancer. DNMT3B is a methyltransferase that is enhanced in several primary tumors. However, the mechanism by which de novo methylation is established in genes related to cancer is not well understood.
SCIENTIFIC REPORTS
(2022)
Review
Cell Biology
Gayeon Kim, Seyeon Lim, Kwang Dong Kim
Summary: NDRG2 is a tumor suppressor gene that enhances cell susceptibility to apoptosis in various physiological environments, such as development, hypoxia, nutrient deprivation, and cancer drug treatment, thereby slowing tumor progression and inhibiting metastasis.
Article
Cell Biology
Kailing Zhou, Yu Sun, Dan Dong, Chenghai Zhao, Wei Wang
Summary: EMP3 acts as a potential tumor suppressor in breast cancer by inhibiting cell cycle progression, DNA repair, and stem-like properties, leading to enhanced sensitivity of breast cancer cells to DNA-damaging agents.
CELL DEATH & DISEASE
(2021)
Article
Oncology
Ningning Zhu, Yueyang Yang, Haitong Wang, Peng Tang, Hongdian Zhang, Haiyan Sun, Lei Gong, Zhentao Yu
Summary: CSF2RB has been found to play an important role in the tumor microenvironment of LUAD. It is expressed at a lower level in tumor tissues compared to normal tissues. Low expression of CSF2RB is associated with poor survival and is an independent risk factor for prognosis in LUAD patients, regardless of chemotherapy or radiotherapy. High expression of CSF2RB is associated with early T, N, and clinical stages. CSF2RB is involved in various immune-related pathways and correlates positively with infiltrating CD4+ T cells, macrophages, NK cells, and monocytes in LUAD. The study suggests that CSF2RB could be a potential target for cancer treatment and has prognostic value in LUAD patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biology
Nina Tanaskovic, Mattia Dalsass, Marco Filipuzzi, Giorgia Ceccotti, Alessandro Verrecchia, Paola Nicoli, Mirko Doni, Daniela Olivero, Diego Pasini, Haruhiko Koseki, Arianna Sabo, Andrea Bisso, Bruno Amati
Summary: Loss of Mga and PRC1.6 has no significant impact on Myc-induced lymphomagenesis in transgenic mice, but loss of Pcgf6 accelerates tumor formation. This suggests an unexpected tumor suppressor activity of Pcgf6 independent of Mga and PRC1.6.
LIFE SCIENCE ALLIANCE
(2022)
Editorial Material
Hematology
Ian J. Majewski
Summary: The study investigates how loss of the tumor suppressor gene Cux1 modulates DNA repair activity in the hematopoietic compartment and contributes to the pathogenesis of therapy-related myeloid neoplasms.
Article
Biochemistry & Molecular Biology
Yongcong Yan, Pinbo Huang, Kai Mao, Chuanchao He, Qiaodong Xu, Mengyu Zhang, Haohan Liu, Zhenyu Zhou, Qiming Zhou, Qianlei Zhou, Bing Ou, Qinghua Liu, Jianhong Lin, Ruibin Chen, Jie Wang, Jianlong Zhang, Zhiyu Xiao
Summary: The study revealed that PTPN13 is associated with HBV-related HCC, and its low expression is linked to poor prognosis. PTPN13 inhibits cell proliferation and tumorigenesis through various mechanisms, and its axis with IGF2BP1 and c-Myc plays a crucial role in metabolic reprogramming.
Article
Multidisciplinary Sciences
Wei Li, Junjie Kou, Zhenxi Zhang, Haoyue Li, Li Li, Wenjing Du
Summary: Research reveals that MYC gene plays an important role in driving T cell lymphomagenesis, and malic enzyme 2 (ME2), an enzyme associated with glutamine metabolism, is essential in this process. By establishing a CD4-Cre; Myc flox/+ transgenic mouse model, it is found that knockout of Me2 significantly suppresses T cell lymphomagenesis. Mechanistically, MYC up-regulates ME2 to maintain redox homeostasis, while ME2 stimulates mTORC1 activity through adjusting glutamine metabolism, promoting MYC translation. Overall, these findings highlight the crucial role of ME2 in MYC-driven T cell lymphomagenesis and suggest the MYC-ME2 circuit as a potential target for TCL therapy.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2023)
Article
Oncology
David Klinkebiel, Wa Zhang, Stacey N. Akers, Kunle Odunsi, Adam R. Karpf
MOLECULAR CANCER RESEARCH
(2016)
Article
Cell Biology
G. Hua, C. He, X. Lv, L. Fan, C. Wang, S. W. Remmenga, K. J. Rodabaugh, L. Yang, S. M. Lele, P. Yang, A. R. Karpf, J. S. Davis, C. Wang
CELL DEATH & DISEASE
(2016)
Article
Oncology
Xiangmin Lv, Chunbo He, Cong Huang, Guohua Hua, Zhengfeng Wang, Steven W. Remmenga, Kerry J. Rodabough, Adam R. Karpf, Jixin Dong, John S. Davis, Cheng Wang
MOLECULAR CANCER THERAPEUTICS
(2017)
Article
Cell Biology
Zhan Wang, Xingcheng Chen, Mei-Zuo Zhong, Shuping Yang, Jiuli Zhou, David L. Klinkebiel, Adam R. Karpf, Yuanhong Chen, Jixin Dong
CELLULAR SIGNALLING
(2018)
Article
Multidisciplinary Sciences
Carter J. Barger, Wa Zhang, Ashok Sharma, Linda Chee, Smitha R. James, Christina N. Kufel, Austin Miller, Jane Meza, Ronny Drapkin, Kunle Odunsi, David Klinkebiel, Adam R. Karpf
SCIENTIFIC REPORTS
(2018)
Article
Oncology
Amit K. Srivastava, Ananya Banerjee, Tiantian Cui, Chunhua Han, Shurui Cai, Lu Liu, Dayong Wu, Ri Cui, Zaibo Li, Xiaoli Zhang, Guozhen Xie, Karuppaiyah Selvendiran, Srinivas Patnaik, Adam R. Karpf, Jinsong Liu, David E. Cohn, Qi-En Wang
Article
Biochemistry & Molecular Biology
Ashok Sharma, Mustafa Albahrani, Wa Zhang, Christina N. Kufel, Smitha R. James, Kunle Odunsi, David Klinkebiel, Adam R. Karpf
Article
Oncology
Carter J. Barger, Connor Branick, Linda Chee, Adam R. Karpf
Article
Oncology
Moinul Haque, Jing Li, Yung-Hsing Huang, Meaad Almowaled, Carter J. Barger, Adam R. Karpf, Peng Wang, Will Chen, Suzanne D. Turner, Raymond Lai
Article
Oncology
Wa Zhang, David Klinkebiel, Carter J. Barger, Sanjit Pandey, Chittibabu Guda, Austin Miller, Stacey N. Akers, Kunle Odunsi, Adam R. Karpf
Article
Biology
Carter J. Barger, Linda Chee, Mustafa Albahrani, Catalina Munoz-Trujillo, Lidia Boghean, Connor Branick, Kunle Odunsi, Ronny Drapkin, Lee Zou, Adam R. Karpf
Summary: FOXM1 and RHNO1 are co-amplified and co-expressed in high-grade serous carcinoma, and their bidirectional promoter may serve as a potential therapeutic target for ovarian and other cancers. Their oncogenic properties in HGSC cells highlight the significance of targeting the FOXM1/RHNO1 gene pair in cancer therapy.
Article
Biochemistry & Molecular Biology
Ling Yin, Yongji Zeng, Renya Zeng, Yuanhong Chen, Tian-Li Wang, Kerry J. Rodabaugh, Fang Yu, Amarnath Natarajan, Adam R. Karpf, Jixin Dong
Summary: PKR plays a critical role in cancer treatment by regulating sensitivity to paclitaxel through controlling Bcl2 expression, presenting as a potential therapeutic target for recurrent drug-resistant ovarian tumors.
Review
Oncology
Cassie Liu, Carter J. Barger, Adam R. Karpf
Summary: Ovarian cancer is a lethal disease with a low 10-year survival rate worldwide, and the aberrant expression and activation of FOXM1 is a key molecular alteration in this cancer. FOXM1 is a master transcriptional regulator that promotes critical oncogenic phenotypes in ovarian cancer, making it a potential target for cancer therapy.
Article
Oncology
Elizabeth A. Griffiths, Pragya Srivastava, Junko Matsuzaki, Zachary Brumberger, Eunice S. Wang, Justin Kocent, Austin Miller, Gregory W. Roloff, Hong Yuen Wong, Benjamin E. Paluch, Linda G. Lutgen-Dunckley, Brandon L. Martens, Kunle Odunsi, Adam R. Karpf, Christopher S. Hourigan, Michael J. Nemeth
CLINICAL CANCER RESEARCH
(2018)
Article
Oncology
Susan R. Sturgeon, J. Richard Pilsner, Kathleen F. Arcaro, Kaoru Ikuma, Haotian Wu, Soon-Mi Kim, Nayha Chopra-Tandon, Adam R. Karpf, Regina G. Ziegler, Catherine Schairer, Raji Balasubramanian, David A. Reckhow
BREAST CANCER RESEARCH
(2017)